I'll research CTSH thoroughly before writing the preview. Let me start by gathering recent earnings materials, news, and stock data.The stock has been on a dramatic ride — from ~$85 in January to a low near $39 in late June, now recovering to ~$50. This mirrors a sector-wide selloff (ACN, INFY too). Let me dig into the most recent earnings materials and guidance.This is rich material. Let me get the year-ago comparison quarter (June 2025, labeled "2025Q2") and understand the dramatic sector selloff with recent news.Let me pull CTSH-specific news over the past two weeks to capture analyst actions and the drivers behind the selloff.I now have what I need. Let me verify a couple of quick calculations before writing.# Cognizant (CTSH) — Q2 2026 Earnings Preview
The number that frames this print isn't a revenue figure — it's the chart. CTSH entered 2026 around $81, peaked near $87 in mid-January, then collapsed to a low of roughly $39 in late June (a ~55% peak-to-trough drawdown) before bouncing ~30% into the report to close at $50.33 on July 28. Even after the bounce, the stock sits ~38% below where it started the year.
Critically, this was not company-specific — it was a sector-wide derating. Accenture (ACN) and Infosys (INFY) traced almost the identical arc (ACN roughly $288 → $124 → $165). The driver was a wholesale repricing of the "AI will cannibalize labor-based IT services" thesis, and the CTSH pre-earnings digest confirms the mood: sentiment is cautious "amid concerns about AI disruption and displacement, alongside recent negative industry data points." The backdrop into the print is a broader tech risk-off — a chip rout dragging the Nasdaq 100 toward correction, with capital rotating toward economically sensitive and "anti-tech" names.
Net implication: at ~$50, CTSH trades at roughly 8.8x the midpoint of its own FY26 adjusted-EPS guide ($5.63–$5.77) — a fraction of its historical mid-teens multiple. Expectations are low, positioning is washed out, and the bar to clear is more about narrative (is the AI thesis existential or manageable?) than about a penny of EPS.
| Metric | Consensus / Guide | Context |
|---|---|---|
| Revenue | ~$5.49B, ~+4.7% YoY | Company guided $5.45–$5.52B (+3.8–5.3% reported; +3.2–4.7% CC) |
| Adjusted EPS | ~$1.38 | vs. $1.31 a year ago |
| Acquisition contribution | ~150 bps to growth | Includes partial-quarter Astreya + 3Cloud |
Consensus of $5.49B sits right at the guidance midpoint — so a simple in-line quarter is broadly priced. The comparison base is tough: the year-ago June quarter grew +7.2% CC (with ~400 bps from the Belcan deal), so the headline is a clear organic deceleration, which is expected.
1) The full-year guide is the whole ballgame. Management last quarter held FY26 CC revenue guidance at 4.0%–6.5% but flagged "a more cautious near-term view of discretionary spending" for Q2, with the midpoint explicitly assuming a discretionary recovery in H2. That H2 hockey stick rests on two pillars management named: (a) large-deal ramps from strong Q4/Q1 bookings reaching "full potential" in June/July, and (b) two full quarters of Astreya. Given the macro deterioration since April and the sector's negative data points, the key question is whether they maintain, narrow, or trim the 4–6.5% CC range. A hold (especially if bookings stay strong) would be a relief; any cut confirms the bears. Note the math is back-end loaded — after Q1 ($5.41B) and the Q2 guide (~$5.49B), the implied H2 run-rate steps up meaningfully.
2) Bookings & book-to-bill — the bull case's backbone. This has been the standout. Q1 bookings grew +21% YoY (7 large deals, 1 mega deal >$500M; +70% large-deal TCV), on top of +18% the prior June quarter (which had two $1B+ mega deals). TTM bookings hit $29.6B, +11%, a ~1.4x book-to-bill. Watch two nuances: (i) whether large-deal momentum persists into a third quarter, and (ii) the ACV vs. TCV divergence — management noted ACV was flat last quarter as deal durations lengthened and small discretionary work stayed soft. Strong TCV masking weak short-cycle demand is exactly the pattern skeptics worry about.
3) Segment dispersion. - Financial Services (~30% of revenue) is the engine — +10%+ CC last quarter across banking and insurance; investors will want confirmation this holds. - Health Sciences (~29%) has been the drag — roughly flat, hurt ~300 bps by lower third-party product pass-through and regulatory/policy uncertainty. Watch the TriZetto/Palantir angle. - Products & Resources (~24%) — stable but exposed to tariff/trade/supply-chain uncertainty. - CMT (~16%) — growth has been flattered by low-margin third-party product pass-through (~10 pts in Q1) and pressured by client-specific dynamics at a large comms/media account. Watch the quality of growth: pass-through revenue inflates the top line but dilutes gross margin.
4) Margins and Project Leap execution. Management raised FY26 adjusted operating margin guidance to 16.0%–16.2% (20–40 bps expansion) on the back of Project Leap, a restructuring targeting $200–300M of in-year savings (~2/3 reinvested in AI/offerings, ~1/3 in reskilling). This quarter should carry the first meaningful severance/restructuring charges ($230–320M total program cost, mostly in 2026, excluded from adjusted numbers). Watch (a) whether the raised margin guide holds, and (b) gross-margin trajectory — Q1 gross margin fell ~80 bps on bench investment, integrated-offering (pass-through) mix, and the November wage hike. Leap is explicitly meant to fix cost-of-delivery.
5) The AI question — the reason the stock is where it is. Everything above is secondary to whether management can convince investors that AI is a tailwind, not a wrecking ball. The bear view: AI-assisted coding (management says ~40% of code is now AI-assisted) deflates billable hours and compresses pricing. Management's counter-narrative to listen for: - "AI Velocity Gap" / "AI builder" positioning — capturing the gap between AI spend and realized value. - Token metering and "AI-infused rate cards" (the A0–A3 human-to-autonomous continuum) — the claim that Cognizant can keep productivity gains rather than passing them all to clients ("bid-to-did" healthy). - The three "vectors" (AI-led productivity → industrializing AI → agentifying the enterprise) and >5,000 AI engagements. - Evidence that AI unlocks net-new work (mainframe/legacy modernization becoming economical, e.g., "$10 → $1.50 per line of mainframe code") and vendor-consolidation wins, offsetting deflation.
Any hard data point — revenue-per-employee, pricing trends, deal economics — that substantiates "productivity we keep" vs. "productivity we give away" will move the stock more than the EPS beat/miss.
6) M&A, capital return, and housekeeping. - Astreya (IT managed services / AI infra build-out): watch close timing and contribution — it's a key H2 revenue lever. - Capital return: FY26 plan of ~$1.6B (~$1B buyback + dividend), ~$1.5B remaining on authorization, net cash ~$0.9B. At a single-digit multiple, buyback commentary matters. - The ongoing evaluation of a potential India primary offering / secondary listing. - Headcount (357,600, growing; hiring more freshers in 2026) and attrition (~12.3%) as signals of demand confidence.
Bull case: Beat/meet on revenue, FY guide held, bookings momentum extends, FS stays double-digit, margin raise reaffirmed, and management lands the "AI is accretive / we keep the productivity" message. Against an 8–9x multiple and washed-out sentiment, that combination can drive a sharp relief rally — the ~30% bounce off the lows suggests some investors are already positioning for it.
Bear case: Organic growth decelerates further, the H2 discretionary recovery is walked back / FY guide trimmed, ACV stays soft even as TCV looks fine, gross margin disappoints, and — most damaging — any admission of AI-driven pricing deflation. That validates the structural de-rating and the stock retests the lows.
CTSH goes into this print as a de-rated, low-expectations, high-narrative-beta name. The financials will likely land close to a guided in-line quarter (~$5.49B revenue, ~$1.38 EPS); the stock's reaction hinges on two things the model can't fully capture: (1) the credibility of the second-half re-acceleration embedded in full-year guidance, and (2) whether management can reframe AI from an existential threat into a growth-and-margin story. Bookings strength and the Project Leap margin lever are the bulls' ammunition; the flat ACV, soft discretionary spend, and pass-through-flattered growth are the bears'. Watch the guidance revision and the AI/pricing commentary first — the EPS number second.
Note on fiscal labeling: this "Q2 2026" report covers the quarter ended June 30, 2026; the year-ago comparison is the June 2025 quarter (revenue $5.25B, +7.2% CC, adjusted EPS $1.31).